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Traumatic brain injury (TBI) produces profound and lasting neuroinflammation that has
both beneficial and detrimental effects. Recent evidence has implicated microRNAs
(miRNAs) in the regulation of inflammation both in the periphery and the CNS. We
examined the expression of inflammation associated miRNAs in the context of TBI
using a mouse controlled cortical impact (CCI) model and found increased levels
of miR-21, miR-223 and miR-155 in the hippocampus after CCI. The expression of
miR-155 was elevated 9-fold after CCI, an increase confirmed by in situ hybridization
(ISH). Interestingly, expression of miR-155 was largely found in neuronal nuclei as
evidenced by co-localization with DAPI in MAP2 positive neurons. In miR-155 knock
out (KO) mice expression of type I interferons IFNα and IFNβ, as well as IFN regulatory
factor 1 and IFN-induced chemokine CXCL10 was decreased after TBI relative to wild
type (WT) mice. Unexpectedly, miR-155 KO mice had increased levels of microglial
marker Iba1 and increased neuronal degeneration as measured by fluoro-jade C
(FJC) staining, suggesting a neuroprotective role for miR-155 in the context of TBI.
This work demonstrates a role for miR-155 in regulation of the IFN response and
neurodegeneration in the aftermath of TBI. While the presence of neuronal nuclear
miRNAs has been described previously, their importance in disease states is relatively
unknown. Here, we show evidence of dynamic regulation and pathological function of a
nuclear miRNA in TBI.
Keywords: gene expression, injury, neurodegeneration, inflammation

INTRODUCTION
Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. In the
US, 2.4 million people suffer a TBI each year (Coronado et al., 2012) and more than
three million people are living with a long-term disability from a TBI (Zaloshnja et al.,
2008). Aside from the primary mechanical injury to the brain, several secondary mechanisms
contribute to morbidity and mortality; these include blood-brain barrier dysfunction, free
radical production, mitochondrial dysfunction, excitotoxicity and inflammation (Finnie, 2013).
Inflammation in the brain of TBI patients has been found as long as 18 years following
injury and likely contributes to long-term cognitive dysfunction (Johnson et al., 2013).
Abbreviations: CCI, controlled cortical impact; IFN, Interferon; miRNA, microRNA; TBI, traumatic brain injury.
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Therefore, targeting neuroinflammation and its downstream
effects may be the key to improving TBI outcomes. It is well
established that inflammatory cytokines and other inflammatory
mediators can negatively affect neuronal survival (Giulian et al.,
1994; Fitch et al., 1999) and function (Hauss-Wegrzyniak et al.,
2002; Di Filippo et al., 2013). However, the mechanisms driving
this dysfunction are still unclear. Several clinical trials aimed
at reducing overall inflammation using steroids, hypothermia,
hypertonic saline and eicosanoids have failed to show therapeutic
efficacy (Hinson et al., 2015). These failures highlight a need for a
more nuanced understanding of inflammation and it’s regulation
in the context of TBI.
MicroRNAs (miRNAs) are emerging as critical regulators
of immune signaling in the systemic immune system and
the CNS, for detailed review please see Ksiazek-Winiarek
et al. (2013), Thounaojam et al. (2013) and Cardoso et al.
(2016). MiRNAs are small non-coding RNAs that are powerful
post-transcriptional regulators. Mature ∼22-nucleotide miRNAs
target mRNA transcripts through complementary base-pairing
to the 3′ UTR (Valencia-Sanchez et al., 2006). This causes target
mRNA degradation or translational inhibition, allowing miRNAs
to regulate the cell proteome. Through this mechanism miRNA
regulate nearly all biological processes, including nervous system
development, function and disease (Kosik, 2006). It is known
that certain miRNAs can be induced by inflammatory stimuli.
Among these are miR-155 (O’Connell et al., 2007), miR-21
(Löffler et al., 2007), miR-146 (Taganov et al., 2006), and
miR-223 (Ceppi et al., 2009). What effects inflammationassociated miRNAs have on neuroinflammation in the context
of TBI are unknown. Several miRNA profiling studies have
shown global changes in miRNA expression after TBI in rodent
models (Lei et al., 2009; Redell et al., 2009; Hu et al., 2012; Liu
et al., 2014; Sun et al., 2014; Meissner et al., 2016), but there
is limited knowledge about the function of these molecules in
the context of brain injury. Multiple groups studying miR-21
have identified a role for this miRNA in neuroprotection
and blood-brain barrier integrity after TBI (Ge et al., 2014,
2015; Han et al., 2014), indicating that miRNAs can affect
TBI outcomes. Additionally, miRNAs can regulate other TBI
relevant pathways, such as reactive oxidation (Zhang X. et al.,
2012), excitotoxicity (Harraz et al., 2012), and even psychiatric
outcomes, including major depression and suicide (Serafini et al.,
2014).
We hypothesized that miRNAs known to be induced by
inflammatory signaling pathways would be elevated after TBI
and impact downstream inflammation and outcomes. Several
miRNAs are known to be induced by inflammatory stimuli (Dai
and Ahmed, 2011; O’Connell et al., 2012; Singh et al., 2013).
Four of these miRNAs, miR-155, miR-21, miR-223 and miR-146
were differentially expressed in at least one miRNA profiling
experiment performed in rodent models of TBI (Lei et al., 2009;
Redell et al., 2009; Hu et al., 2012; Liu et al., 2014; Sun et al.,
2014; Meissner et al., 2016). To study the role of inflammationassociated miRNAs in TBI, we utilized a mouse controlled
cortical impact (CCI) model. In the CCI model, a pneumatically
driven piston is used to impact the exposed dura creating a
unilateral injury to the left parietal cortex, resulting in measurable
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motor and memory deficits (Saatman et al., 2006). We primarily
focus on miR-155, which we found robustly increased after TBI.
Using a miR-155 knock out (KO) mouse, we examined the role
of miR-155 in TBI.

MATERIALS AND METHODS
Animals
Male C57BL/6 mice were obtained from Charles River
Laboratories Inc. (Wilmington, MA, USA). MiR-155 KO
mice (Dagan et al., 2012), strain B6.Cg-Mir155tm1.1Rsky/J,
were purchased from Jackson labs (Bar Harbor, MA, USA).
C57BL/6 mice were used as wild type (WT) controls for miR-155
KO experiments. All mice were group housed in a 12 h light-dark
cycle and fed ad libitum. All procedures and protocols were
approved by the Institutional Animal Care and Use Committee
of the University of Nebraska Medical Center and conducted in
accordance with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals.

Controlled Cortical Impact
Seven to nine week-old male mice were anesthetized using
5% inhaled isoflurane, their heads were shaved and placed in
a Kopf stereotaxic head frame where they were maintained
under anesthesia using 2% isoflurane. A 4-mm craniotomy was
performed midway between lambda and bregma on the left side.
The exposed dura was then impacted using a Precision Systems
and Instrumentation TBI-0310 (Fairfax Station, VA, USA) at a
speed of 3.5 m/s with a 200 ms dwell time. This procedure was
similar to previous reports (Mattson and Scheff, 1994; Smith
et al., 1995). Injury depths of 0.5 and 1.0 mm were used to
simulate moderate and severe injuries, respectively. After injury,
Surgicel (Johnson and Johnson, Dallas, TX, USA) was placed
over the injury site, the removed skull was adhered back to its
original place with dental cement and the wound closed with
wound clips. 0.5% bupivacaine with 1:200,000 epinephrine was
used as an analgesic. Naïve animals were not exposed to injury,
craniotomy or anesthesia.

Tissue Preparation for Histology
Paraffin-embedded tissues were used for Luxol fast blue,
terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) and fluorescent in situ hybridization (FISH). Brains
were submersion fixed in 4% PFA overnight before processing;
staining was performed on 5 µm sections. Iba1 and fluorojade C (FJC) staining were performed on fixed-frozen tissues.
Transcardial perfusion was performed on anesthetized mice with
cold PBS and 2.5% sucrose followed by PBS with 2.5% sucrose
and 4% PFA. Brains were submersion fixed an additional 24 h,
cryoprotected in 30% sucrose, frozen with 2-methyl butane on
dry ice and stored at −80◦ C. A 4 mm coronal section, including
the injury site was sectioned into 50 µm slices and every fifth
section was collected in 0.1 M phosphate buffer.

Luxol Fast Blue Staining
After hydration to 95% ethanol, slides were stained with filtered
0.1% Luxol fast blue in a solution of 0.5% acetic acid at 60◦ C

2

July 2017 | Volume 10 | Article 228

Harrison et al.

miR-155 Promotes Interferon after Injury

overnight. The next day slides were rinsed in 95% ethanol
followed by distilled water then differentiated in 0.05% lithium
carbonate for 1 min and 70% ethanol for 1 min. Slides were
counterstained with 0.5% cresyl violet for 30 min at 60◦ C, rinsed
in distilled H2 O, and differentiated in 95% ethanol for 5 min.
Coverslips were mounted using Cytoseal (Thermo, Waltham,
MA, USA). Slide scanning was performed by the UNMC tissue
sciences facility using a Ventana’s Coreo Au Slide Scanner at 40×
magnification.

Jefferson, AR, USA) and 0.0001% DAPI (Sigma, St. Louis, MO,
USA) in 1% acetic acid. Tissue was then dried in a 60◦ C oven and
incubated in xylene for 1 min, then coverslips were mounted with
DPX (Sigma, St. Louis, MO, USA). For each brain, three slices
between bregma −2.5 and −1.5 were imaged for quantification.
FJC positive cells were counted using ImageJ (Schneider et al.,
2012) by a blinded observer. The average number of fluoro-jade
positive cells per slice is reported.

Terminal Deoxynucleotidyl Transferase
dUTP Nick End Labeling (TUNEL)

RNA Isolation, cDNA Synthesis and Real
Time PCR
Tissue was isolated from the hippocampus and RNA was
extracted using TRIzol (Life Technologies, Carlsbad, CA, USA)
according to manufacturer’s instructions. TaqMan miRNA
and Gene Expression Assays (Life Technologies, Carlsbad,
CA, USA) were used for cDNA synthesis and real time
PCR according to manufacturer’s instructions. Small nuclear
RNA U6 (U6) was used as a control for miRNA studies and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used
as a control for mRNA studies. Delta-delta Ct method was used
to calculate fold change (2−((CtmiRNA − CtU6 )exp − (CtmiRNA − CtU6 )control ) )
or (2−((CtmRNA − CtGAPDH )exp − (CtmRNA − CtGAPDH )control ) ). Statistical
significance was determined using ∆Ct values (CtmiRNA − CtU6 )
or (CtmRNA − CtGAPDH ).

ApopTag Peroxidase in situ apoptosis detection kit (Millipore,
Temecula, CA, USA) was used for TUNEL staining according
to manufacturer’s directions in conjunction with TSA plus
cyanine 5 kit (PerkinElmer, Waltham, MA, USA). Briefly,
hydrated slides were treated with 20 µg/mL proteinase K, then
terminal deoxynucleotidyl transferase (TdT) was used to transfer
digoxigenin (DIG) labeled nucleotides onto fragmented DNA.
The tail of DIG labeled nucleotides was then detected using
an anti-DIG antibody conjugated to peroxidase. A TSA plus
cyanine 5 kit (PerkinElmer, Waltham, MA, USA) was used
to develop the fluorescent stain and nuclei were stained with
DAPI.

In Situ Hybridization
ISH was performed as described previously (Chaudhuri et al.,
2013). In brief, double DIG-labeled LNA probes (Exiqon,
Vedbaek) were used in conjunction with anti-DIG-POD, Fab
fragments (Roche, Basel) and TSA plus cyanine 5 (PerkinElmer,
Waltham, MA, USA). To reduce background, a 10 min 3%
H2 O2 peroxidase quenching step was added to the original
protocol. MAP2 antibody (ab5392, abcam, Cambridge) was used
at 1:1000 dilution; nuclei were stained with DAPI.

Protein Analysis
Protein was isolated from ipsilateral hippocampal tissue using
TRIzol (Life Technologies, Carlsbad, CA, USA) according to
manufacturer’s instructions. Equal amounts of protein samples
were separated by SDS-PAGE and transferred to a nitrocellulose
membrane. The membrane was blocked in Superblock (Pierce,
Waltham, MA, USA) and incubated overnight at 4◦ C with
primary antibodies. After washing, membrane was incubated
with infrared secondary antibodies (LI-COR, Lincoln, NE, USA)
for 1 h at room temperature. Imaging and densitometry was
performed with an Odyssey Imaging System (LI-COR, Lincoln,
NE, USA). The following antibodies and concentrations were
used for Western blotting: suppressor of cytokine signaling 1
(SOCS1; 1:1000, 38-5200, Thermo, Waltham, MA, USA),
caspase 3 (1:1000, 9662, Cell Signaling, Danvers, MA, USA),
beta-actin (AM1829B, 1:20,000, Abgent, San Diego, CA, USA).
For statistical analysis, each sample was normalized to beta-actin.

Immunohistochemisty
Free-floating cryosections were incubated with 3% H2 O2
to quench endogenous peroxidase. After thorough washing
sections were blocked with 10% normal goat serum (NGS)
+0.3% Triton-X100 in PBS. Tissues were incubated with
Iba1 (Wako, Kampenhout; 1:500) in 0.3% Triton-X100 +3%
NGS in PBS at 4◦ C overnight. ImmPRESS HRP Anti-Rabbit
IgG (Vector labs, Burlingame) was used as a secondary and
DAB Plus substrate system (Thermo, Waltham, MA, USA)
was used for developing. Sections were then mounted on
gelatin-coated slides, allowed to dry overnight, incubated in
xylene for 1 min, and mounted with Cytoseal (Thermo,
Waltham, MA, USA). Slides were imaged using a light
microscope at 100× magnification. Images were quantified
using ImageJ (Schneider et al., 2012) to calculate the percent
area covered by Iba1 staining in the hippocampus and
cortex.

Statistics
For comparisons between two groups an unpaired two-tailed
student’s T-test was used to calculate significance. For
comparisons between multiple groups two-way ANOVAs
followed by Bonferroni post hoc tests were employed. For testing
significance of multiple parameters, such as the expression
of several genes, between two groups a false discovery rate
calculation was used. All statistical tests were performed with
GraphPad Prism (La Jolla, CA, USA). P < 0.05 was considered
significant. For data represented in graphs, the mean ± SEM is
shown. A minimum of three biological replicates was used for all
experiments.

Fluoro-Jade C (FJC) Staining
Free-floating cryosections were mounted on gelatin coated
slides and air-dried overnight. Slides were incubated in 0.06%
potassium permanganate followed by 0.0001% FJC (Histochem,
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FIGURE 1 | Controlled cortical impact (CCI) increases inflammation-associated microRNAs (miRNAs) in the hippocampus. (A) Anatomical characterization of
moderate CCI 1, 3, or 7 days post injury (DPI), myelin (Blue) and Nissl (Purple). (B) Staining for apoptotic cells using terminal deoxynucleotidyl transferase dUTP nick
end labeling (TUNEL; magenta), nucleus (blue). Images show ipsilateral hemisphere 1 day after moderate CCI in the hippocampus and the lesion boundary of the
cortex. Scale bars = 50 µM. (C) Levels of inflammatory cytokines and (D) inflammation-associated miRNAs in the ipsilateral (IPSI) and contralateral (CONTRA)
hippocampus 1, 3, 7 and 14 days after CCI by qPCR at 0.5-mm injury depth and in naïve animals (n = 3). (E) Anatomical characterization of severe CCI 3 DPI (left)
and levels of miRNA in the hippocampus (right) were measured 3 days after injury by qPCR in naïve (n = 4), sham (n = 4), moderate CCI (n = 3), and severe CCI mice
(n = 4). Data are expressed as fold change relative to naïve mice. The mean ± SEM are shown. # P < 0.05; ## P < 0.01; ### P < 0.001 by two way ANOVA.
∗
P < 0.05; ∗∗∗ P < 0.001 by Bonferroni post hoc testing relative to the contralateral hemisphere.

RESULTS

(Figure 1B). To confirm that inflammatory signaling was
present in the hippocampus, we measured the expression
of pro-inflammatory cytokines IL-1β, TNFα and IL-6
in the hippocampus 1, 3, 7 and 14 days after injury by
qPCR. As expected based on previous reports, expression
of pro-inflammatory cytokines was increased acutely after
CCI in the injured (ipsilateral) compared to the uninjured
(contralateral) hippocampus (Figure 1C). This indicated that
the hippocampus was a suitable region for studying regulation
of inflammation by miRNAs while limiting the confounding role
of apoptosis.
Expression of miR-155 (UUAAUGCUAAUUGUGAUA
GGGGU),
miR-21(UAGCUUAUCAGACUGAUGUUGA),
miR-223 (UGUCAGUUUGUCAAAUACCCCA) and miR-146

CCI Increased Expression of
Inflammation-Associated miRNAs in the
Hippocampus
CCI produced a cortical lesion, and white matter damage
to the underlying corpus callosum and alveus was evident
later time points (Figure 1A). Given that apoptosis can
occur in TBI and may be influenced by the miRNAs
of interest, we examined the level of apoptosis in the
cortex and hippocampus. Importantly, apoptosis in the
hippocampus is limited compared to the cortical lesion
boundary, which shows high levels of TUNEL staining
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FIGURE 2 | Nuclear, neuronal localization of miR-155 in the hippocampus after CCI. (A) Fluorescence in situ hybridization (FISH) for miR-155 1, 3 and 7 days after
moderate CCI and in naïve mice. Dentate gyrus (DG), CA1 and CA3 of the ipsilateral hippocampus are shown. (B) miR-155 expression in the ipsilateral DG of wild
type (WT) and miR-155 knock out (KO) mice 3 days after severe CCI. (C) FISH and Co-IHC was performed for neuronal marker MAP2 (green), nuclei (blue), miR-155
(magenta). Scale bars = 50 µM.

post hoc test did not reveal significance for miR-223 expression
at these time points. Expression of miR-146 was not altered
by CCI at the time points examined by two way ANOVA
(P = 0.16). Increasing the injury severity from moderate
to severe, 0.5 mm and 1.0 mm depth respectively, revealed
significantly increased expression of miR-155, miR-21 and
miR-223 at 3 days post-injury (DPI) as determined by two-way
ANOVA. Bonferroni post hoc analysis showed that miR-155,
miR-223 and miR-21 were all elevated in the ipsilateral as
compared to the contralateral hemisphere 3 days after severe
CCI, whereas only miR-155 was also elevated after moderate CCI
(Figure 1E). In summary, inflammation-associated miRNAs are

(UGAGAACUGAAUUCCAUGGGUU) was examined in
hippocampi of the injured (ipsilateral) and the uninjured
(contralateral) hemisphere from the same animals at 1, 3, 7 and
14 days after moderate CCI and in naïve controls (Figure 1D).
In naïve animals, there was no difference in miRNA expression
between hemispheres. CCI significantly increased expression of
miR-155, miR-21 and miR-223 in the ipsilateral compared to
the contralateral hippocampus by two-way ANOVA. Bonferroni
post hoc analysis showed that the difference in miR-155 reached
statistical significance at day 1, 3 and 7 whereas, expression
of miR-21 was significantly increased at 14 days after CCI
(P = 0.035), but not at earlier time points, day 1, 3 and 7. The

Frontiers in Molecular Neuroscience | www.frontiersin.org

5

July 2017 | Volume 10 | Article 228

Harrison et al.

miR-155 Promotes Interferon after Injury

FIGURE 3 | miR-155 KO mice have a dampened hippocampal interferon (IFN) response to CCI. (A) Levels of pro-inflammatory cytokines IL-6, TNFα and IL1β, and
(B) IFNs, IFN regulatory factor 1 (IRF1) and IFN-induced chemokines in the ipsilateral hippocampus were measured 3 days after severe CCI by qPCR in miR-155 KO
and WT mice. Data are expressed as fold change relative to WT, the mean ± SEM are shown (n = 4). ∗ FDR < 0.05. (C) Brains from WT and miR-155 KO mice were
stained for Iba1 3 days after severe CCI. Representative images are shown. (D) Quantification of Iba1 staining of WT (n = 5) and miR-155 KO (n = 6) ipsilateral
hippocampi. The mean ± SEM are shown. ∗ P = 0.046 by Student’s T-test. (E) Levels of suppressor of SOCS1 and SHIP1 mRNA and (F) SOCS1 protein in the
ipsilateral and contralateral hippocampus were measured 3 days after severe CCI in WT (n = 4) and KO (n = 4) mice by qPCR and Western blot respectively. The
mean ± SEM from are shown. ∗∗ P = 0.0072 by Student’s T-test.

FISH revealed prolonged elevation of miR-155 at 1, 3 and 7 days
after moderate CCI as well as 3 days after severe CCI in the
hippocampus, similar to that observed by qPCR (Figures 2A,B).
Expression of miR-155 was also observed in the boundary
zone of the cortex (Supplementary Figure S1A). Importantly,
no fluorescent signal was detected in miR-155 knockout (KO)
mice, confirming FISH specificity (Figure 2B). Interestingly,
expression of miR-155 was largely nuclear and present at high
levels in the laminar layers of the hippocampus, structures

elevated in the ipsilateral hippocampus after TBI and in general
showed a more prolonged increase compared to the expression
of cytokines IL-1β, TNFα and IL-6, which peaked 1 day after
injury. Of the miRNAs examined, miR-155 alone was significant
at all time points measured up to 7 days after moderate injury.
Considering the strong induction of miR-155, the function of
miR-155 in TBI was further investigated.
To examine the cell type-specific localization of miR-155 in
the injured brain, we performed FISH. Examining miR-155 by
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FIGURE 4 | Increased hippocampal neurodegeneration in miR-155 KO mice after CCI. Degenerating neurons were stained with fluoro-jade C (FJC; green) and DAPI
(blue) 3 days after 1.0-mm CCI in the brains of WT (n = 5) and miR-155 KO (n = 6) mice. (A) Representative images from the ipsilateral DG. (B) Quantification of FJC
positive cells in the DG. The mean ± SEM is shown. ∗ P < 0.05 by Student’s T-test. (C) Representative images of full-length and cleaved caspase 3 and beta-actin
(Actin) analyzed by Western blot in WT and miR-155 KO ipsilateral hippocampi 3 days after 1.0-mm CCI. (D) Quantification of the percentage of cleaved Caspase
3 relative to full-length Caspase 3. The mean ± SEM are shown, (n = 4).

ipsilateral hippocampus compared to control mice (P = 0.046 by
Student’s T-test; Figures 3C,D). These data suggest that miR-155
is not essential for the activation of microglia after TBI and
implies that a dampened microglial response is not responsible
for the reduction in IFN signaling observed in miR-155 KO
mice.
We hypothesized that previously validated miR-155 targets
SOCS1 and SHIP1 mediated miR-155 regulation of IFN signaling
in the context of TBI. However, compared to the expression
found in WT mice, no increase in SOCS1 was observed in
miR-155 KO mice at the mRNA or protein level after TBI
(Figures 3E,F). In fact there was a significant decrease in
SOCS1 mRNA expression in miR-155 KO mice (P = 0.007 by
student’s T-test). Therefore, miR-155 regulation of IFN signaling
in TBI is likely independent of SOCS1. We also tested SHIP1,
a second target of miR-155 known to regulate IFN signaling
and found no significant change in mRNA expression by
qPCR. In summary, miR-155 KO mice show a decreased
expression of type 1 IFNs and IFN regulated genes without
evident decreases in microglial activation or increased SOCS1 or
SHIP1 expression.

composed primarily of neurons. Co-staining for miR-155 and
neuronal marker MAP2 confirmed that miR-155 was expressed
at high levels in neuronal nuclei in both the hippocampus and
cortex (Figure 2C, Supplementary Figure S1B). Together with
qPCR data, FISH clearly shows elevation of miR-155 after CCI.

Interferon Signaling Is Dampened in
miR-155 KO Mice
In order to understand the function of miR-155 in regulating
the immune response in TBI, we subjected miR-155 KOs and
WT mice to CCI. Three days after CCI, RNA was isolated
from ipsilateral hippocampi and expression of cytokines and
chemokines were measured by qPCR. Unexpectedly, there
were no differences in the expression of IL-6, IL-1β or TNFα
(Figure 3A), which are regulated by miR-155 in other systems.
However, miR-155 KO mice had decreased expression of 6/9 IFN
related genes measured (FDR < 0.05), including IFNα2, IFNα4,
IFNα5 and IFNβ1, as well as IFN regulatory factor 1 (IRF1)
and IFN induced chemokine CXCL10 (Figure 3B). Overall, we
found a reduction of the IFN response in miR-155 KO mice
after TBI without changes in other TBI induced inflammatory
cytokines.
To examine the importance of miR-155 in microglial
activation in the context of TBI, we examined the levels of
microglial marker Iba1 in hippocampal slices 3 days after CCI in
miR-155 KO and WT mice. In miR-155 KO mice we observed an
increase rather than the expected decrease in Iba1 staining in the

Frontiers in Molecular Neuroscience | www.frontiersin.org

Increased Neurodegeneration in miR-155
KO Mice
Since miR-155 was highly increased in neuronal nuclei, the
effect of miR-155 ablation on neuronal degeneration and
apoptosis in the hippocampus was measured. Fluoro-jade C
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upregulation, up to 9-fold and extending to 7 days after
CCI. Using a miR-155 KO mouse, we identified a role
for miR-155 in promoting the expression of IFN genes,
including IFNα2, IFNα4, IFNα5 and FNβ1, as well as
IRF1 and IFN induced chemokine CXCL10. Surprisingly,
we found that miR-155 was highly expressed in neuronal nuclei
suggesting potential non-canonical functions of this miRNA
in TBI. Additionally, we found that miR-155 KO mice had
increased neurodegeneration and microgliosis, indicating a
neuroprotective role for miR-155 in neuronal injury. This work
confirms that miR-155 regulates neuroinflammation and also
provides evidence that miR-155 plays a role in the neuronal
response to TBI.
Increasing evidence points to important functions for
inflammation-associated miRNAs in neurological disease (Buller
et al., 2010; Yelamanchili et al., 2010; Harraz et al., 2012;
Zhang L. et al., 2012; Ge et al., 2014). Among the miRNAs
associated with neuroinflammation, miR-155 is the best
characterized, having well-documented roles in several disease
models. Inhibiting or reducing miR-155 improved outcomes
in several neural disease models involving neuroinflammation,
such as Parkinson’s disease (Thome et al., 2016), Alzheimer’s
disease (Guedes et al., 2014), amyotropic lateral sclerosis (Koval
et al., 2013; Parisi et al., 2013; Butovsky et al., 2015b), stroke
(Eisenhardt et al., 2015), and alcohol induced inflammation
(Lippai et al., 2013). Intriguingly, miR-155 mice are also
highly susceptible to HSV encephalitis (Bhela et al., 2014).
Our data indicate that TBI produces a robust increase in
miR-155 at 1, 3 and 7 DPI with a return to baseline by
14 days. Increased expression after TBI was confirmed by
ISH. Expression of miR-155 is induced by TNFα (O’Connell
et al., 2007) and IL-1β (Stanczyk et al., 2008). TNFα and IL-1β
mRNA expression increased dramatically after TBI, 200 fold
and 50 fold from naive respectively. Therefore, we propose
that TNFα and IL-1β signaling leads to miR-155 expression
after TBI.
Surprisingly, miR-155 was detected in the nucleus of cells.
Nuclear miRNAs have been shown to mediate gene expression
changes in non-canonical ways such as alternative splicing
and chromatin modification in addition to post-transcriptional
inhibition (Roberts, 2014). Some additional functions include
degradation of long non-coding RNAs, disruption of pri-miRNA
processing, and transcriptional activation (Rasko and Wong,
2017). Differential CLIP-Seq of miR-155 KO cells by Loeb et al.
(2012) revealed many non-canonical miR-155 binding sites,
including sites in small nucleolar RNAs (snoRNAs). Nuclear
localization of miRNAs has been reported in neurons, but
what role nuclear-neuronal miRNAs play in development and
disease is largely unknown (Khudayberdiev et al., 2013). Here we
describe a nuclear-neuronal miRNA that was not only induced
in a neurological condition, but also played a functional role in
disease processes. This discovery paves the way for the study of
nuclear-neuronal miRNA in neurological disease.
In the brains of miR-155 KO mice the type 1 IFN response
was decreased. This is consistent with the findings of several
other groups studying the role of miR-155 in the immune
system (Zhou et al., 2010). IFNβ is increased after both murine

FIGURE 5 | After traumatic brain injury inflammatory cytokines tumor necrosis
factor alpha (TNFα), interleukin 6 (IL-6), and interleukin 1 beta (IL-1β) increase
and induce miR-155 expression in the injured hippocampus. miR-155
promotes type 1 interferon (IFN) though an unknown mechanism independent
of SOCS1 and SHIP1. Also, expression of miR-155 has a neuroprotective
effect after injury.

(FJC) staining for degenerating neurons showed evidence of
neurodegeneration both in the cortex and hippocampus. In the
hippocampus FJC positive cells were found predominately
in the Dentate gyrus (DG). The DG in miR-155 KO
mice had significantly more FJC positive cells relative to
controls (P = 0.046 by Student’s T-test; Figures 4A,B),
indicating that miR-155 KO mice had increased hippocampal
neurodegeneration. Consistent with TUNEL staining of the
hippocampus, there were low levels of caspase 3 cleavage
in both groups, 10% and 20% for WT miR-155 KO
mice respectively, a difference that was not significant
(P = 0.20 by Student’s T-test; Figures 4C,D). Overall we
found increased hippocampal neurodegeneration in miR-155
KO mice, without significant evidence of increased apoptosis.
Figure 5 graphically summarizes our main findings on miR-155
in TBI.

DISCUSSION
Neuroinflammation has a complex role in TBI playing both
beneficial and detrimental roles (Finnie, 2013). Understanding
the regulation and downstream effects of inflammation in
the context of brain injury will help unravel this seeming
duplicitous process. The expression of inflammation-associated
miRNAs was examined in the CCI mouse model of TBI.
Inflammation-associated miRNAs miR-155, miR-21 and
miR-223 were increased in the hippocampus after CCI. Of
the miRNAs examined, miR-155 showed the most consistent
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Alternatively, the neuroprotective effects of miR-155 may be
independent of IFN signaling and relate to either canonical or
non-canonical regulation of gene expression within neurons.
Further in vitro studies on miR-155 in neurons would help
elucidate the mechanisms by which this miRNA regulates
neurodegeneration.
In the brain, miRNAs regulate neuronal plasticity and
neuroprotection (Kosik, 2006). Several of these processes have
relevance to TBI, where both neurogenesis and regeneration are
known to occur (Nudo, 2011). In addition, miRs have been
associated with psychiatric disorders found in TBI survivors,
such as major depression (Serafini et al., 2014). For example,
increased miR-185 was found in the brains of suicide completers
and linked with decreased TrkB-T1 (Maussion et al., 2012). We
have shown that miR-155 is neuroprotective in the acute period
after TBI, but further exploration of this and other miRNA in the
chronic phase of TBI is warranted.
This study has several limitations. One important limitation is
the focus on pathology and gene expression in the hippocampus.
We show by qPCR that miR-155 is increased in the hippocampus
after TBI. We also found increased hippocampal and cortical
expression of miR-155 by FISH. The expression and function
of miR-155 in other regions was not examined, but may be
relevant to the overall importance of miR-155 in TBI. This
work focused on a specific subset of miRNAs, but there is a
growing list of other non-coding RNAs. These include long
non-coding RNAs (lncRNAs), endogenous siRNAs (esiRNA)
and piwi-interacting RNAs (piRNAs). Epigenetic regulation by
non-coding RNAs likely plays critical roles in the response
to CNS injury through chromatin remodeling, transcriptional
activation and gene silencing (Esteller, 2011).
These findings clearly show a functional role for miR-155
in the mouse CCI model of TBI, although additional studies in
other models of TBI as well as in human patients are necessary to
show miR-155 is clinically relevant. Understanding the complex
cell signaling, gene expression and epigenetic mechanisms that
occur in the wake of TBI is important for improving therapeutic
approaches. This work highlights changes in miRNAs, large-scale
regulators of protein expression. The elevation of these miRNAs
suggests that they play a role in the pathophysiology of TBI.
These data show that miR-155 can affect TBI pathophysiology,
but whether miR-155 expression can improve or worsen disease
outcomes is a critical question that remains to be addressed.

and human TBI (Karve et al., 2016). Toll-like receptors and
other pattern recognition receptors (PRRs) are responsible for
stimulating type 1 IFNs in response to viral RNA (Honda and
Taniguchi, 2006). In TBI, IFN induction could be mediated by
a variety of damage associated molecular patterns (DAMPS)
released upon injury (Gesuete et al., 2014). For example we
have shown that miRNA containing TLR7 recognition motifs are
secreted in extracellular vesicles after TBI (Harrison et al., 2016).
Karve et al. (2016) showed that deletion of the IFNA1 receptor
improved outcomes in murine TBI and that these effects were
mediated by hematopoietic cells. In addition to hematopoietic
cells, neurons can both express and respond to type 1 IFNs
(Delhaye et al., 2006; Rosato and Leib, 2015). Therefore, it is
possible that in the context of TBI miR-155 promotes IFN
expression in neurons.
Despite evidence that miR-155 promotes microglial activation
in vitro (Cardoso et al., 2012), we did not see a reduction
in microgliosis in miR-155 KO after CCI mice as measured
by Iba1 staining density. This study only provides a limited
characterization of microglial activation and it is possible that
by using markers more specific to microglial activation or
examining a more extended time course that alteration in
microglial activation may be present in miR-155 KO mice after
TBI. Therefore, we cannot rule out the importance of miR-155
for microglial activation, but we argue that the role for miR-155
in response to CNS injury extends beyond glial activation.
Specifically, expression of miR-155 in MAP2 expressing neurons
suggests that this miRNA may have an equally important role in
neurons as in glia.
There is evidence that miR-155 contributes to
neuroinflammation by reducing SOCS1 protein levels in
microglia and astrocytes (Cardoso et al., 2012; Butovsky et al.,
2015a). SOCS1 is a negative regulator of IFN signaling and a
validated target of miR-155 (Wang et al., 2010) that functions
to inhibit STAT1, a key transcription factor for IFN signaling
(Nakagawa et al., 2002). In miR-155 KO mice there was
decreased expression of IFN and IFN response genes after TBI,
but no corresponding increase in SOCS1 at the protein or mRNA
level. Instead, we found a slight decrease in SOCS1 mRNA. These
data suggest that in the context of TBI, SOCS1 does not mediate
potentiation of the IFN response by miR-155. We also found no
change in expression of SHIP1, a validated target of miR-155
also known to inhibit IFN expression (O’Connell et al., 2009;
Gabhann et al., 2010; Figure 5). This does not preclude the
possibility that other canonical mRNA targets are involved.
However, the nuclear localization of miR-155 also opens the
possibility for non-canonical regulation of gene expression,
which should also be explored.
Importantly, we found that in addition to regulating
neuroinflammation, miR-155 also influenced neurodegeneration
as measured by fluoro-jade C (FJC) staining. It is possible
that autocrine or paracrine IFN signaling is neuroprotective
and inhibition of IFNs and IFN-related genes in miR-155
KO mice promotes neurodegeration. Though the mechanisms
are incompletely understood, IFNβ is a main line therapy
for multiple sclerosis where it has been shown to have both
anti-inflammatory and neuroprotective effects (Kieseier, 2011).
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Summary
We have identified miR-155 as a TBI induced miRNA that
promotes the type 1 IFN response. In the context of TBI, miR-155
is strongly expressed in neuronal nuclei, suggesting that it may
regulate gene expression through non-canonical mechanisms.
Increased neurodegeneration in miR-155 KO mice points to a
neuroprotective role for miR-155 in TBI.
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